MTOR and small cell lung carcinoma: Genomic analysis of 51 SCLC cases also found genetic alterations in the PI3K/AKT/mTOR pathway in 36% of the samples, with mutations in PIK3CA (6%), PTEN (4%), AKT2 (9%), AKT3 (4%), RICTOR (9%), and mTOR (4%) [3].